MaxCyte signs strategic platform licence with Catamaran Bio

By

Sharecast News | 04 Jan, 2023

17:21 17/05/24

  • 375.00
  • 0.00%0.00
  • Max: 381.19
  • Min: 370.00
  • Volume: 9,978
  • MM 200 : n/a

Commercial cell engineering company MaxCyte announced the signing of a strategic platform licence (SPL) with Catamaran Bio on Wednesday.

Last news

Week ahead: Fedspeak, UK CPI, global PMIs in focus
Sector movers: Miners pace gains
Europe close: Stocks end on mixed note
London close: Stocks recoup some earlier losses
Broker tips: FRP Advisory, AutoTrader